NO20051577L - Azaaren-derivater - Google Patents
Azaaren-derivaterInfo
- Publication number
- NO20051577L NO20051577L NO20051577A NO20051577A NO20051577L NO 20051577 L NO20051577 L NO 20051577L NO 20051577 A NO20051577 A NO 20051577A NO 20051577 A NO20051577 A NO 20051577A NO 20051577 L NO20051577 L NO 20051577L
- Authority
- NO
- Norway
- Prior art keywords
- general formula
- optionally substituted
- group represented
- alkyl
- azaaren
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002253123 | 2002-08-30 | ||
US46469003P | 2003-04-22 | 2003-04-22 | |
PCT/JP2003/010964 WO2004020434A1 (ja) | 2002-08-30 | 2003-08-28 | 含窒素芳香環誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20051577L true NO20051577L (no) | 2005-05-27 |
Family
ID=31980530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20051577A NO20051577L (no) | 2002-08-30 | 2005-03-29 | Azaaren-derivater |
Country Status (15)
Country | Link |
---|---|
US (3) | US20060004029A1 (ru) |
EP (1) | EP1522540A4 (ru) |
JP (1) | JP4183193B2 (ru) |
KR (1) | KR100732440B1 (ru) |
CN (1) | CN100339376C (ru) |
AU (1) | AU2003261807B9 (ru) |
BR (1) | BR0313871A (ru) |
CA (1) | CA2488739A1 (ru) |
IL (1) | IL165762A0 (ru) |
MX (1) | MXPA05001536A (ru) |
NO (1) | NO20051577L (ru) |
NZ (1) | NZ538617A (ru) |
RU (1) | RU2310651C2 (ru) |
TW (1) | TW200413353A (ru) |
WO (1) | WO2004020434A1 (ru) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60134679D1 (de) | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische Heterozyklen |
EP1604665B1 (en) * | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase inhibitor |
EP1683785B1 (en) * | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Urea derivative and process for producing the same |
JP4503022B2 (ja) | 2003-12-23 | 2010-07-14 | ファイザー・インク | 新規キノリン誘導体 |
WO2006030941A1 (ja) | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
PE20060664A1 (es) * | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
ES2322175T3 (es) | 2004-09-17 | 2009-06-17 | EISAI R&D MANAGEMENT CO., LTD. | Composicion medicinal con estabilidad mejorada y gelificacion reducida. |
GB0421525D0 (en) * | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
EP1824821A2 (en) * | 2004-11-23 | 2007-08-29 | PTC Therapeutics, Inc. | Carbazole, carboline and indole derivatives useful in the inhibition of vegf production |
WO2007015569A1 (ja) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
JP4989476B2 (ja) * | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
WO2007026864A1 (ja) * | 2005-09-01 | 2007-03-08 | Eisai R & D Management Co., Ltd. | 崩壊性の改善された医薬組成物の製造方法 |
EP1760076A1 (en) | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
US20090053236A1 (en) * | 2005-11-07 | 2009-02-26 | Eisai R & D Management Co., Ltd. | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
EP1964837A4 (en) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Antitumor agent against multiple myeloma |
GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
WO2007136103A1 (ja) * | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
JPWO2008001956A1 (ja) | 2006-06-29 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝線維症治療剤 |
WO2008026748A1 (fr) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
KR101445892B1 (ko) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암 치료용 조성물 |
WO2008128231A1 (en) * | 2007-04-16 | 2008-10-23 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
US7889523B2 (en) * | 2007-10-10 | 2011-02-15 | Freescale Semiconductor, Inc. | Variable load, variable output charge-based voltage multipliers |
US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
MX2010008187A (es) * | 2008-01-29 | 2010-08-10 | Eisai R&D Man Co Ltd | Uso combinado de inhibidor de angiogenesis y taxano. |
RU2011111728A (ru) | 2008-08-29 | 2012-10-10 | Топотаргет А/С (Dk) | Новые производные мочевины и тиомочевины |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
AU2011254550B2 (en) | 2010-05-21 | 2013-11-07 | Noviga Research Ab | Novel pyrimidine derivatives |
BR112012032462A2 (pt) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase. |
JP5886411B2 (ja) | 2011-03-24 | 2016-03-16 | ノビガ・リサーチ・エービーNoviga Research AB | 新規のピリミジン誘導体 |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
ES2661073T3 (es) | 2011-07-15 | 2018-03-27 | Gea Food Solutions Bakel B.V. | Un dispositivo de tratamiento térmico que comprende una antena de radiometría de microondas |
JP6277198B2 (ja) | 2012-11-05 | 2018-02-07 | ナント ホールディングス アイピー,エルエルシー | 置換インドール−5−オール誘導体及びそれらの治療適用 |
MX2015004979A (es) | 2012-12-21 | 2015-07-17 | Eisai R&D Man Co Ltd | Forma amorfa de derivado de quinolina y metodo para su produccion. |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
JP2016514703A (ja) | 2013-03-15 | 2016-05-23 | ナントバイオサイエンス、インコーポレイテッド | 置換インドール−5−オール誘導体及びそれらの治療適用 |
ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
CN106660997B (zh) | 2014-08-18 | 2019-05-21 | 卫材R&D管理有限公司 | 单环吡啶衍生物的盐及其晶体 |
JP2017206437A (ja) * | 2014-08-18 | 2017-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 4−アミノピリジン誘導体 |
BR112017002827B1 (pt) | 2014-08-28 | 2023-04-18 | Eisai R&D Management Co., Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
WO2016054483A1 (en) * | 2014-10-03 | 2016-04-07 | Novartis Ag | Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
MX2017010474A (es) | 2015-02-25 | 2017-11-28 | Eisai R&D Man Co Ltd | Metodo para suprimir el amargor de un derivado de quinoleina. |
RU2701188C2 (ru) | 2015-02-27 | 2019-09-25 | Нэнтбайосайенс, Инк. | Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения |
KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
SG11201710198YA (en) | 2015-06-16 | 2018-01-30 | Eisai R&D Man Co Ltd | Anticancer agent |
PL3660004T3 (pl) | 2016-10-11 | 2023-10-02 | Arvinas Operations, Inc. | Związki i sposoby do ukierunkowanej degradacji receptora androgenowego |
CA3091153A1 (en) | 2018-03-28 | 2019-10-03 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
TW202136240A (zh) | 2019-12-19 | 2021-10-01 | 美商亞文納營運公司 | 用於靶向降解雄激素受體之化合物及方法 |
CA3181782A1 (en) | 2020-05-09 | 2021-11-18 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016348A1 (en) | 2000-08-09 | 2002-02-28 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
DE60134679D1 (de) * | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische Heterozyklen |
WO2002044156A2 (en) * | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
-
2003
- 2003-08-28 CN CNB038202719A patent/CN100339376C/zh not_active Expired - Fee Related
- 2003-08-28 WO PCT/JP2003/010964 patent/WO2004020434A1/ja active IP Right Grant
- 2003-08-28 EP EP03791389A patent/EP1522540A4/en not_active Withdrawn
- 2003-08-28 BR BR0313871-2A patent/BR0313871A/pt not_active IP Right Cessation
- 2003-08-28 CA CA002488739A patent/CA2488739A1/en not_active Abandoned
- 2003-08-28 AU AU2003261807A patent/AU2003261807B9/en not_active Ceased
- 2003-08-28 NZ NZ538617A patent/NZ538617A/en unknown
- 2003-08-28 KR KR1020057003337A patent/KR100732440B1/ko not_active IP Right Cessation
- 2003-08-28 JP JP2004532761A patent/JP4183193B2/ja not_active Expired - Fee Related
- 2003-08-28 RU RU2005108999/04A patent/RU2310651C2/ru not_active IP Right Cessation
- 2003-08-28 MX MXPA05001536A patent/MXPA05001536A/es active IP Right Grant
- 2003-08-28 US US10/521,074 patent/US20060004029A1/en not_active Abandoned
- 2003-08-29 US US10/651,496 patent/US7109219B2/en not_active Expired - Lifetime
- 2003-08-29 TW TW092123981A patent/TW200413353A/zh unknown
-
2004
- 2004-12-14 IL IL16576204A patent/IL165762A0/xx unknown
-
2005
- 2005-03-29 NO NO20051577A patent/NO20051577L/no not_active Application Discontinuation
-
2006
- 2006-08-18 US US11/507,082 patent/US7468380B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2004020434A1 (ja) | 2004-03-11 |
AU2003261807B2 (en) | 2007-01-04 |
EP1522540A4 (en) | 2011-08-10 |
JP4183193B2 (ja) | 2008-11-19 |
US7468380B2 (en) | 2008-12-23 |
CA2488739A1 (en) | 2004-03-11 |
US20050187236A1 (en) | 2005-08-25 |
RU2310651C2 (ru) | 2007-11-20 |
NZ538617A (en) | 2005-12-23 |
JPWO2004020434A1 (ja) | 2005-12-15 |
IL165762A0 (en) | 2006-01-15 |
US20060004029A1 (en) | 2006-01-05 |
CN1678607A (zh) | 2005-10-05 |
BR0313871A (pt) | 2005-07-19 |
TW200413353A (en) | 2004-08-01 |
EP1522540A1 (en) | 2005-04-13 |
RU2005108999A (ru) | 2005-08-27 |
KR20050059151A (ko) | 2005-06-17 |
MXPA05001536A (es) | 2005-04-19 |
AU2003261807B9 (en) | 2007-02-15 |
KR100732440B1 (ko) | 2007-06-27 |
AU2003261807A1 (en) | 2004-03-19 |
CN100339376C (zh) | 2007-09-26 |
US7109219B2 (en) | 2006-09-19 |
US20070004764A1 (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20051577L (no) | Azaaren-derivater | |
DK1277736T3 (da) | Hidtil ukendte bicykliske forbindelser | |
SG160195A1 (en) | N-phenyl-2-pyrimidine-amine derivatives | |
RS50537B (sr) | Derivati benzimidazola i njihovo korišćenje kao antagonista receptora a ii | |
GB0113233D0 (en) | Chemical compounds | |
MXPA03011722A (es) | Derivados de piperidina utiles como moduladores de actividad de quimiocina. | |
NO20080157L (no) | Fremgangsmate for syntese av organiske forbindelser | |
PH12009500610A1 (en) | 4-imidazolin-2-one compounds | |
DE3876813D1 (de) | 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a. | |
DE60239170D1 (de) | Bicyclische Verbindungen | |
NO20062936L (no) | Fremgangsmate for fremstilling av N-alkyl-2(hydroksy-4-benzoyl)-3-benzofuraner og dets mellomprodukter derav | |
TR199500954A1 (tr) | Yeni pirokarbazoller. | |
ES2001105A6 (es) | Un procedimiento para la preparacion de derivados de dihidropiridinas. | |
HUP0200144A2 (hu) | Eljárás peszticid hatású 5-amino-1-aril-3-cianopirazol-származékok előállítására és az új köztitermékek | |
MXPA04004650A (es) | Proceso para preparacion de amidas de acido alfa-hidrocaroxilico. | |
MXPA04004676A (es) | Azetidinil diaminas utiles como lingandos del receptor de nociceptina orl-1. | |
EG24798A (en) | Pyrazole compound. | |
TW200503733A (en) | T-shaped channel blockers | |
ZA200208986B (en) | Process for the preparation of pesticidal compounds. | |
DK0979822T3 (da) | Fremgangsmåde til fremstilling af 2-carbamoyl-pyridiner | |
NO20052854L (no) | Substituerte alkylpyridazinoner for behandlingen av hukommelses- og laeresvikt. | |
IL152859A0 (en) | Process for the preparation of pesticidal compounds and intermediates thereof | |
NO20064058L (no) | Fremgangsmate for fremstilling av 1,5-d ifenylpyrazolkarboksylsyrederlvat | |
HUP0202296A2 (hu) | Eljárás szubsztituált benzizotiazolszármazékok előállítására | |
WO2003106425A3 (fr) | Phenyl- et pyridyl-diazaheterocycles ayant une activite modulatrice du tnf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |